Yousif Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Yousif Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,229	Closed	-$76.2K	–	1986
2023 Q1	$76.2K	Sell	7,229 -699	-9%	-$21.1K	﹤0.01%	1918
2022 Q4	$269K	Sell	7,928 -2,114	-21%	-$102K	﹤0.01%	1745
2022 Q3	$482K	Sell	10,042 -210	-2%	-$12.5K	0.01%	1526
2022 Q2	$584K	Sell	10,252 -748	-7%	-$47.2K	0.01%	1483
2022 Q1	$889K	Sell	11,000 -7	-0.1%	-$1.04K	0.01%	1395
2021 Q4	$2.23M	Buy	+11,007	New	+$2.39M	0.02%	899

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Yousif Capital Management's NKTR Position: Q2 2023 in Review

Yousif Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 7,229 shares — an estimated $76.2K sold.

Yousif Capital Management first reported a position in NKTR in Q4 2021 and held it in 6 quarters. The position peaked at $2.23M in Q4 2021. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Yousif Capital Management reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Yousif Capital Management sold 7,229 Nektar Therapeutics shares in Q2 2023, an estimated $76.2K.
Yousif Capital Management first reported a position in Nektar Therapeutics in Q4 2021 and held it in 6 quarters.
Yousif Capital Management's Nektar Therapeutics position peaked at $2.23M in Q4 2021.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Yousif Capital Management's 13F filing for Q2 2023, filed 2 Aug 2023.